Psorcast Mobile Study
NCT05621369 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000
Last updated 2025-06-11
Summary
The purpose of this study is to understand variation in the symptoms of psoriasis and psoriatic arthritis using simple, scalable smartphone-based measurements. This study uses an iPhone app to record these symptoms through questionnaires and sensors.
Conditions
- Psoriatic Arthritis
- Psoriasis
- Psoriatic Conditions
- Dermatologic Disease
- Rheumatologic Disease
- Psoriatic Nail
- Plaque Psoriasis
- Joint Pain
- Dactylitis
Interventions
- BEHAVIORAL
-
Participant self-assessment surveys
At enrollment, participants are asked to complete a baseline health history, family history, and a participant-reported symptom inventory.
- BEHAVIORAL
-
Psoriasis Draw
Participants are asked to draw the location and size of psoriasis they currently experience. Participants are provided a body template onto which they can draw on their screen. Investigators estimate the percentage of body area affected.
- BEHAVIORAL
-
Psoriasis Area Photo
Participants are asked to take a picture of a representative psoriasis plaque and indicate the location of the plaque. They are asked to take a picture of the same area over time. The investigators are developing computer vision algorithms to assess the plaque.
- BEHAVIORAL
-
Finger and Toe Photos
Participants are asked to take pictures of the back of each hand and the top of each foot. These photos can be used to assess finger and toe swelling as well as psoriatic nail involvement. The investigators are developing computer vision algorithms to assess psoriatic nail involvement and digit swelling.
- BEHAVIORAL
-
Digital Jar Open
Participants are asked to internally and externally rotate the phone as it rests on a flat surface. Participants perform each direction (internal and external) and each arm (left and right) in turn. Gyroscope sensors measure the degree of rotation.
- BEHAVIORAL
-
30 Second Walk
Participants are asked to walk in a straight line for 30 seconds. Gait is measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
- OTHER
-
Psorcast mobile application
Participants complete all described behavioral interventions via a dedicated iPhone app, Psorcast.
Sponsors & Collaborators
-
Brigham and Women's Hospital
collaborator OTHER - collaborator OTHER
- collaborator OTHER
-
Harvard Medical School (HMS and HSDM)
collaborator OTHER -
New York University
collaborator OTHER -
Sage Bionetworks
lead OTHER
Principal Investigators
-
Solveig Sieberts, Ph.D · Sage Bionetworks
-
Jose Scher, MD · NYU Langone Medical Center
-
Joseph Merola, MD, MMSc · Brigham and Women's Hospital & Harvard Medical School
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2022-01-01
- Primary Completion
- 2027-01-31
- Completion
- 2027-01-31
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Effect of Deucravacitinib on Quality of Life in Participants With Plaque Psoriasis in a Community Setting
NCT05701995 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of HS-10374 Compared to Placebo in Adults With Active Psoriatic Arthritis
NCT06176508 ·Status: RECRUITING ·Phase: PHASE2
-
Study Evaluating The Prevalence Of Undiagnosed Psoriatic Arthritis In Patients With Plaque Psoriasis
NCT00998829 ·Status: COMPLETED
-
Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis
NCT05272150 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate the Efficacy of Infliximab Induction Therapy for Patients With Palmoplantar Psoriasis (PPP)(Study P04555)(COMPLETED)
NCT00686686 ·Status: COMPLETED ·Phase: PHASE3
-
Cytokine Expression in Psoriasis Patients with and Without Joint Involvement
NCT05307809 ·Status: RECRUITING ·Phase: NA
-
AsseSSing Impact in pSoriatic Treatment
NCT05171270 ·Status: COMPLETED
-
Personal Precise Treatment on Psoriasis and Psoriatic Arthritis
NCT04915105 ·Status: UNKNOWN ·Phase: NA
-
Study to Evaluate Psoriasis Severity and Its Psychosocial Impact Using the Simplified Psoriasis Index (SPI), as Well as Long-term Safety, Tolerability and Efficacy of Secukinumab Administered Subcutaneously in Patients With Moderate to Severe Psoriasis
NCT02595970 ·Status: COMPLETED ·Phase: PHASE3
-
Psoriasis Longitudinal Assessment and Registry
NCT00508547 ·Status: ACTIVE_NOT_RECRUITING
-
A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and Retreatment
NCT02207244 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)
NCT01392326 ·Status: COMPLETED ·Phase: PHASE3
-
Exploratory Study on Quality of Life in Patient With Moderate Psoriasis and Moderate Psoriatic Arthritis
NCT01139918 ·Status: COMPLETED
-
Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis
NCT01925768 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Demonstrate the Efficacy, Safety and Tolerability of Intravenous Secukinumab up to 52 Weeks in Subjects With Active Psoriatic Arthritis
NCT04209205 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Safety and Tolerability, and the Efficacy of Si-544 in Adults With Psoriasis Vulgaris or Psoriatic Arthritis
NCT06191042 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Guselkumab Versus Placebo for the Treatment of Low Body Surface Area Moderate Plaque Psoriasis
NCT06039189 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNFα Inhibitor Treatment
NCT04908189 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome
NCT03440736 ·Status: COMPLETED ·Phase: PHASE4
-
24 Week Efficacy and 3-year Safety and Efficacy of Secukinumab in Active Psoriatic Arthritis
NCT01989468 ·Status: COMPLETED ·Phase: PHASE3
-
An Explorative Psoriasis Biomarker Study
NCT04394936 ·Status: TERMINATED ·Phase: NA
-
Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis
NCT02144857 ·Status: UNKNOWN ·Phase: PHASE4
-
Single Cell Genomics of Psoriatic Skin
NCT02929745 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
NCT02173301 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis
NCT05908240 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA